By integrating results from cellular assays, patient tissue analyses and extensive cancer databases, this study provides comprehensive evidence emphasising the clinical relevance of LAPTM5‐regulated autophagy in venetoclax resistance, suggesting its potential as a therapeutic target for addressing MM progression. Here, LAPTM5 is linked to cancer.